Greenwich LifeSciences (GLSI) News
NASDAQ: GLSIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
19.25-0.54 (-2.73%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GLSI news summary
We found 3 recent headlines mentioning Greenwich LifeSciences (GLSI): 1 in the past week and 1 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, GLSI is down 2.73% at $19.25. The most recent story, "Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026", was published by GlobeNewswire on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Greenwich LifeSciences headlines
- Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026STAFFORD, Texas, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,…GlobeNewswire
- Tuesday Sector Laggards: Biotechnology, Metals & Mining StocksIn trading on Tuesday, biotechnology shares were relative laggards, down on the day by about 3%. Helping drag down the group were shares of Syndax Pharmaceuticals, off about 17% and shares of…NasdaqSNDX, GLSI, AREC, IDR
- Tuesday Sector Laggards: Application Software, Biotechnology StocksIn trading on Tuesday, application software shares were relative laggards, down on the day by about 3%. Helping drag down the group were shares of ODDITY Tech, down about 30.3% and shares of Verra…NasdaqODD, VRRM, GLSI, PRAX